Nuvation Bio Inc.
Nuvation Bio Inc. (NUVB): 12 pipeline candidates · 4 upcoming catalysts · ~20 mo cash runway · 10 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
20.1 months
D/E 0.91 · 0% dilution
Lead: Approved
12 candidates
4 upcoming, next in ~1536d
0 buys · 3 sells (180d)
A transparent, data-derived signal for Nuvation Bio Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.9B
Cash
$125.4M
Quarterly Burn
$79.3M
Runway
20.1 mo
Revenue
$83.2M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (12 candidates)
| Drug | Phase |
|---|---|
| AB-106 | Phase 2 |
| Crizotinib | Phase 3 |
| DS6051b | Phase 1 |
| Enzalutamide | Phase 1 |
| ibtrozi | Approved |
| NUV-1156 | Phase 1 |
| NUV-1176 | Phase 1 |
| NUV-1511 | Phase 1 |
| NUV-868 | Phase 1 |
| Olaparib | Phase 1 |
Showing 10 of 12 candidates. Sign up for full pipeline.
Upcoming Catalysts (4)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
232
Total value held
$859.1M
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 51,989,593 | $223.0M |
| blackrock, inc. | 25,100,374 | $107.7M |
| vanguard capital management llc | 23,252,396 | $99.8M |
| omega fund management, llc | 8,081,089 | $34.7M |
| laurion capital management lp | 7,822,638 | $33.6M |
| state street corp | 6,784,927 | $29.1M |
| geode capital management, llc | 5,863,654 | $25.2M |
| bank of america corp /de/ | 3,219,826 | $13.8M |
| redmile group, llc | 3,153,256 | $13.5M |
| tang capital management llc | 3,149,557 | $13.5M |
Showing top 10 of 232 institutional holders of Nuvation Bio Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Nuvation Bio Inc.'s pipeline?
Nuvation Bio Inc. (NUVB) has 12 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Nuvation Bio Inc.'s lead drug candidate?
Nuvation Bio Inc.'s most advanced tracked candidate is AB-106 (Phase 2) for Solid Tumor; Non Small Cell Lung Cancer.
What is Nuvation Bio Inc.'s next catalyst?
Nuvation Bio Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3 Multicenter Open-label Study of Taletrectinib Versus a Standard of Care ROS1-Tyrosine Kina" — expected September 1, 2030.
What is Nuvation Bio Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Nuvation Bio Inc. has approximately 20.1 months of cash runway.
What is Nuvation Bio Inc.'s market capitalization?
Nuvation Bio Inc.'s market capitalization is approximately $1.9B.
Get the full picture on Nuvation Bio Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.